Mallinckrodt Pays $117M for This Bay Area Biotech and Its Failed Liver Drug Post author:Sam Post published:November 1, 2017 Post category:BioPharma Mallinckrodt has agreed to buy Ocera Therapeutics in a deal that could hit $117M. Source: BioSpace You Might Also Like New Data Reveals This New York Biotech's Pipeline Could be a Game Changer June 15, 2017 Bristol-Myers Squibb, Clovis Oncology Ink Pact to Marry Their PD-1/PARP Drugs in Phase II and III July 30, 2017 Insmed Rockets as Lung Drug Wows in Late-Stage Study September 4, 2017
Bristol-Myers Squibb, Clovis Oncology Ink Pact to Marry Their PD-1/PARP Drugs in Phase II and III July 30, 2017
